Status:
UNKNOWN
NGS Combined With RNAseq on Tumor Immune Escape in NSCLC
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18-75 years
Brief Summary
Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq
Detailed Description
Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq. Detecting non-small cell lung cancer patient NGS and RNA...
Eligibility Criteria
Inclusion
- Non-small cell lung cancer patient First-line chemotherapy with platinum-based chemotherapy
Exclusion
- EGFR mutant positive Alk mutant positive
Key Trial Info
Start Date :
December 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03764917
Start Date
December 1 2018
End Date
December 31 2021
Last Update
March 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China, 200000